Diglifloz Plus 5/850 Mg 30 Tablets

Diglifloz Plus 5/850 mg 30 Tablets

Description:

Diglifloz Plus 5/850 mg is an oral antidiabetic prescription medicine combining dapagliflozin and metformin in one film‑coated tablet. It is used as part of a comprehensive diabetes care plan to help control blood glucose levels in adults with type 2 diabetes mellitus. By targeting both renal glucose reabsorption and hepatic glucose production, Diglifloz Plus supports effective glycemic control, helps reduce HbA1c, and may assist in weight and blood pressure management when used alongside diet and exercise.

Indications:

• Type 2 diabetes mellitus in adults as an adjunct to diet and exercise to improve glycemic control.
• Patients insufficiently controlled on metformin alone or already treated with the combination of dapagliflozin and metformin as separate tablets.
• May be used in combination with other antidiabetic agents (such as insulin or sulfonylureas) when additional glycemic control is needed, as directed by a physician.
• Helps reduce elevated fasting and postprandial blood glucose and lower HbA1c levels.

Active Ingredients / Key Components:

• Dapagliflozin – 5 mg per film‑coated tablet (sodium‑glucose co‑transporter 2 (SGLT2) inhibitor).
• Metformin hydrochloride – 850 mg per film‑coated tablet (biguanide class oral hypoglycemic agent).
• Other excipients (tablet core and film coating) – exact composition and concentrations , please check the product leaflet or the manufacturer’s official website; please refer to the official package insert for full excipient list.

Dosage & Administration / How to Use:

• Use only as prescribed by your physician. Dosage must be individualized based on the patient’s current regimen, renal function, and glycemic response.
• Typical adult dose: One tablet taken orally once or twice daily as directed by the doctor. Do not exceed the prescribed dose.
• Take with meals to reduce the risk of gastrointestinal side effects associated with metformin.
• Swallow the tablet whole with a glass of water. Do not crush, break, or chew the film‑coated tablet.
• If a dose is missed, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed dose.
• Regular monitoring of blood glucose and HbA1c is recommended to assess treatment response.
• Renal function (e.g., eGFR) should be assessed before starting and periodically during treatment; dose adjustment or discontinuation may be required in renal impairment as directed by the physician.

Clinical Benefits:

• Improves glycemic control in adults with type 2 diabetes by combining two complementary mechanisms of action (SGLT2 inhibition and reduction of hepatic glucose production).
• Dapagliflozin promotes urinary glucose excretion (glycosuria) by inhibiting SGLT2 in the kidney, helping lower blood glucose levels independently of insulin.
• Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to reduced fasting and postprandial glucose.
• Clinical studies have shown that adding dapagliflozin to metformin therapy can further reduce HbA1c (approximately 0.6 percentage points versus placebo when added to metformin in trials).
• May support modest weight reduction and blood pressure improvement in some patients due to increased glucose and osmotic diuresis, when combined with lifestyle measures.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to dapagliflozin, metformin, or any component of the formulation.
• Contraindicated in patients with severe renal impairment, end‑stage renal disease, or on dialysis, due to increased risk of metformin accumulation and reduced efficacy of dapagliflozin.
• Metformin is associated with a rare but serious risk of lactic acidosis, particularly in patients with significant renal impairment, liver disease, alcohol abuse, dehydration, severe infection, or in states of hypoxia (e.g., heart failure, respiratory failure). Immediate medical attention is required if symptoms such as unexplained fatigue, muscle pain, breathing difficulty, abdominal pain, or hypothermia occur.
• Dapagliflozin can cause volume depletion and hypotension, especially in elderly patients, those on diuretics, or with low blood pressure. Monitor volume status and blood pressure.
• May increase risk of genital mycotic infections (e.g., vulvovaginal candidiasis, balanitis) and urinary tract infections due to glycosuria. Maintain good personal hygiene and seek medical advice if symptoms develop.
• Risk of ketoacidosis (including euglycemic diabetic ketoacidosis) has been reported with SGLT2 inhibitors. Seek urgent medical care if symptoms such as nausea, vomiting, abdominal pain, excessive thirst, difficulty breathing, confusion, or unusual fatigue occur.
• Use with caution in patients with hepatic impairment, cardiovascular disease, or those at risk of dehydration.
• Temporarily discontinue metformin‑containing products before iodinated contrast imaging procedures or major surgery as recommended by your physician to reduce risk of lactic acidosis.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Use during pregnancy or lactation is generally not recommended unless clearly needed and directed by a specialist.
• Consult your doctor before use if you are taking other medications for diabetes, diuretics, antihypertensives, or drugs that may affect kidney function.
• Not intended for use in type 1 diabetes or for the treatment of diabetic ketoacidosis.
• Keep out of reach of children.

Side Effects:

• Common side effects: Genital fungal infections (e.g., vaginal yeast infections, balanitis), increased urination, urinary tract infections, nausea, diarrhea, abdominal discomfort, metallic taste, and mild gastrointestinal upset (mostly related to metformin), headache, and dizziness.
• Less common but important: Volume depletion (low blood pressure, dizziness, fainting), dehydration, increased creatinine or changes in kidney function tests, rash or hypersensitivity reactions.
• Serious side effects (seek immediate medical attention): Signs of lactic acidosis (rapid breathing, severe weakness, abdominal pain, irregular heartbeat), diabetic ketoacidosis (nausea, vomiting, abdominal pain, difficulty breathing, confusion), severe allergic reactions (swelling of face, lips, tongue, or throat; severe rash), or severe urinary tract infection (fever, flank pain, blood in urine).
• Inform your doctor about any persistent, bothersome, or unexpected side effects.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Serving size: 1 tablet (film‑coated).
• Count: 30 film‑coated tablets per pack.
• Form: Oral tablet.
• Strength per tablet: dapagliflozin 5 mg + metformin hydrochloride 850 mg.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.